Opening a life sciences subsidiary in Italy: three mistakes that international companies keep making

Italy is the second-largest manufacturing economy in Europe, home to 51 IRCCS research hospitals, a universal single-payer healthcare system serving 60 million people, and a clinical research infrastructure that most international biotech and diagnostics companies underestimate. Every year, dozens of life sciences companies decide to establish a physical presence in the country. Many of them make the same three mistakes.

These are not theoretical risks. They are patterns that repeat across geographies, company sizes, and product categories. Understanding them before committing capital can save months of lost time and hundreds of thousands of euros in avoidable costs.

Mistake 1: Treating Italy as a single market

Italy is not one healthcare market. It is twenty-one.

The Italian healthcare system is managed at the regional level, not the national level. Each of the twenty regions and two autonomous provinces operates its own healthcare budget, its own procurement procedures, its own formulary for approved drugs and devices, and its own timeline for technology adoption. A product approved by AIFA, the national drug agency, is not automatically available to patients across the country. It must be included in each region's formulary, and that process has its own logic, its own gatekeepers, and its own timeline.

For an international company entering Italy for the first time, this means that the question is not "should we enter the Italian market?" The question is: "which region do we enter first, with which product, through which clinical centre, and with what reimbursement pathway?"

The differences are not marginal. Lombardy concentrates 43% of the country's therapeutic research and has the highest density of IRCCS centres, including some of Europe's most advanced oncology and genomics institutes. Emilia-Romagna runs one of the most efficient public procurement systems in the country, with structured pathways for innovative medical devices. Lazio offers proximity to AIFA and to the national regulatory decision-makers, which matters when your product requires national-level negotiation before regional adoption.

A company that launches in the wrong region, or that launches nationally without a regional strategy, will spend months discovering that approval in Rome does not mean access in Milan, and that a successful pilot in Turin does not automatically translate to adoption in Naples.

Mistake 2: Ignoring regional incentives

Italy has a complex but surprisingly generous system of incentives for international companies investing in the country. The problem is that most of these incentives are regional, not national, and the system is neither centralised nor easy to navigate from the outside.

Some regions offer structural incentives that are permanently available: corporate tax credits, reductions in IRAP (the regional business tax), preferential access to Special Economic Zones, and co-financing for R&D activities conducted in partnership with local research institutions. Others publish competitive calls for proposals, often with significant budgets, specifically designed to attract foreign direct investment in strategic sectors such as life sciences, digital health, and advanced manufacturing.

Most international companies entering Italy do not even look for these incentives. There are three reasons for this.

First, the information is fragmented. There is no single national portal that aggregates all regional incentive programmes in real time. Each region publishes its own calls on its own website, often only in Italian, with its own eligibility criteria and its own application deadlines.

Second, the application process can be bureaucratically intensive. Regional incentive programmes typically require detailed business plans, financial projections, partnership agreements with local entities, and compliance documentation that international companies are not accustomed to preparing in the Italian format.

Third, many international companies assume that incentives in Southern Europe are small, slow, and not worth the effort. This assumption is wrong. Some regional programmes offer co-financing of up to 50% of eligible R&D costs, direct grants for hiring specialised personnel, and tax benefits that can reduce the effective cost of establishing a subsidiary by 20-30% over the first three years.

The competitive advantage for companies that have a local advisor who understands the regional incentive landscape is real and measurable. Two companies entering Italy with the same product, the same team size, and the same market strategy can end up with dramatically different cost structures, simply because one of them identified and applied for the right regional incentives at the right time.

Mistake 3: Underestimating GDPR and data localisation requirements

This is the mistake that costs the most to fix after the fact.

The European Union has some of the strictest data protection regulations in the world. For life sciences companies that handle clinical data, patient records, genomic information, or diagnostic results, the implications of GDPR and related regulations are not abstract compliance exercises. They are structural constraints that affect the architecture of the company's IT infrastructure, its clinical partnerships, and its credibility with European institutions.

The core principle is straightforward: personal data of EU citizens, especially health data, cannot be transferred outside the European Union without specific legal safeguards. Since the Schrems II ruling invalidated the EU-US Privacy Shield in 2020, those safeguards have become significantly more complex to implement. Standard Contractual Clauses exist but require a case-by-case assessment of the data protection regime in the receiving country, which is a non-trivial legal exercise.

For a biotech or diagnostics company based in the United States, Israel, or Asia, this has a direct operational consequence: clinical data generated in Italian hospitals and IRCCS centres cannot simply be uploaded to a US-based cloud server for analysis. The data must be processed and stored within the EU, by an entity that has a legal basis for processing under GDPR.

This means that an international company conducting clinical validation studies in Italy needs, at minimum: a data processing infrastructure hosted within the EU; a designated Data Protection Officer with documented competence in EU health data regulation; a legal entity or authorised representative in the EU that can serve as the data controller or processor under GDPR; and Data Processing Agreements with every clinical partner, CRO, and subcontractor that touches patient data.

Many companies discover these requirements after they have already signed clinical collaboration agreements with Italian hospitals, after they have already begun collecting data, or after a hospital's own Data Protection Officer raises a flag during a routine compliance review. At that point, the cost of remediation is not just financial. It is reputational. An IRCCS centre that discovers an international partner is handling patient data in a non-compliant way will not simply ask for a corrective action plan. It will freeze the collaboration until compliance is demonstrated, and it will remember.

When does a subsidiary actually make sense?

Not every situation requires a full Italian subsidiary. The decision depends on what the company needs to do in Italy and what legal structures those activities require.

A subsidiary (typically an SRL) makes sense when: the company needs to participate in public procurement or hospital tenders, which require an Italian VAT number and legal entity; the company will employ local staff under Italian labour contracts; the company processes clinical or patient data in volume, requiring a local data controller under GDPR; or the company plans to establish long-term institutional relationships with IRCCS centres, regional health authorities, or AIFA.

A subsidiary may not be necessary when: the initial objective is clinical validation through a single IRCCS partnership; the company wants to test market demand through a distribution agreement with a local partner; or the company is in an early exploratory phase where a representative office can serve as a listening post.

The real cost is not the entity setup. It is the time lost making the wrong choices.

Incorporating an SRL in Italy costs a few thousand euros and takes a few weeks with a competent notary. That is not where the money goes.

The money goes to the months spent discovering that your regional strategy was wrong, that the incentives you could have captured are no longer available, that your clinical data cannot be processed on your existing infrastructure, and that the IRCCS centre you wanted to work with has concerns about your data handling practices.

The real cost of entering Italy without preparation is not the cost of the mistakes themselves. It is the cost of the time it takes to fix them, and the opportunities that expire while you do.

Frequently asked questions